Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results

Blood blood.2024024789.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ibrahim Aldoss, Gregory W Roloff, Anjali S. Advani, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy E O'Connor, Amy Zhang, Katharine Miller, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Ryan D Cassaday, Bijal D. Shah, Rawan Faramand, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 4877.

https://doi.org/10.1182/blood-2023-182404

Published: 2023

Journal Articles

Progression of Disease within 2 Years Predicts Poor Survival in Patients with Classic Hodgkin Lymphoma

Alexandra Kredátusová, Vit Prochazka, Marie Lukasova, Veronika Hanackova, Tomas Papajik, Veronika Bachanova

Blood (2023) 142 (Supplement 1): 6194.

https://doi.org/10.1182/blood-2023-186562

Published: 2023

Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4887.

https://doi.org/10.1182/blood-2023-182837

Published: 2023

Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood (2023) 142 (Supplement 1): 617.

https://doi.org/10.1182/blood-2023-184862

Published: 2023

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco Davila, Claudio Anasetti, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller, Veronika Bachanova, Najla H El Jurdi, Brian C Betts

Blood (2023) 142 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2023-173376

Published: 2023

Journal Articles

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Shernan G. Holtan, Kelly Walton, Najla H El Jurdi, Joseph E. Maakaron, Mark Juckett, Veronika Bachanova, Thomas Myers, Linda J. Paradiso, Todd DeFor, Qing Cao, Brian Betts

Blood (2023) 142 (Supplement 1): 4925.

https://doi.org/10.1182/blood-2023-181292

Published: 2023

Journal Articles

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Gregory W Roloff, Ibrahim Aldoss, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy E O'Connor, Amy Zhang, Katharine Miller, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Ryan D Cassaday, Bijal D. Shah, Rawan Faramand, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2023-182531

Published: 2023

Journal Articles

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Blood (2023) 142 (Supplement 1): 380.

https://doi.org/10.1182/blood-2023-189505

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment

Nuttavut Sumransub, Cassie Seichter, Kateryna Kent, Ryan Shanley, Marie Hu, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeremy R. Allred, Veronika Bachanova, Jeffrey S Miller, Joseph E. Maakaron

Blood (2023) 142 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2023-187070

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2023-184345

Published: 2023

Journal Articles

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

Noam E. Kopmar, Ted Gooley, Gregory W Roloff, Ibrahim Aldoss, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy O'connor, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, Paul Shaughnessy, John Mathews, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Bijal D. Shah, Rawan Faramand, Lori S. Muffly, Ryan D Cassaday

Blood (2023) 142 (Supplement 1): 522.

https://doi.org/10.1182/blood-2023-185107

Published: 2023

Journal Articles

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Rawan Faramand, Noam E. Kopmar, Kaitlyn C Dykes, Nikeshan Jeyakumar, Simone E. Dekker, Vishal K Gupta, Mohamed Ahmed, Aaron C. Logan, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, John Mathews, Paul Shaughnessy, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ryan D Cassaday, Bijal D. Shah, Katharine Miller, Lori S. Muffly, Ahmed Galal, Stephanie B. Tsai, Bhagirathbhai Dholaria

Blood (2023) 142 (Supplement 1): 671.

https://doi.org/10.1182/blood-2023-182566

Published: 2023

Journal Articles

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Chenyu Lin, Stephanie B. Tsai, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Noam E. Kopmar, Simone E. Dekker, Nikeshan Jeyakumar, Vishal K Gupta, Timothy E O'Connor, Kaitlyn C Dykes, Mohamed Ahmed, Bhagirathbhai Dholaria, Hector Zambrano, Danielle Bradshaw, Aaron C. Logan, Sean Tracy, Michal Kubiak, Melhem M. Solh, Santiago Mercadal, Marc Schwartz, Akash Mukherjee, Minoo Battiwalla, Paul Shaughnessy, Navneet Majhail, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Abdullah Ladha, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Joshua Sasine, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Vinod Pullarkat, Ryan D Cassaday, Katharine Miller, Lori S. Muffly, Ahmed Galal, Bijal D. Shah, Rawan Faramand

Blood (2023) 142 (Supplement 1): 3502.

https://doi.org/10.1182/blood-2023-182380

Published: 2023

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Blood (2022) 140 (Supplement 1): 1588–1591.

https://doi.org/10.1182/blood-2022-164674

Published: 2022

NARROW

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Progression of Disease within 2 Years Predicts Poor Survival in Patients with Classic Hodgkin Lymphoma

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only